---

Atropine in Organophosphorus (OP) Poisoning: Mechanism, Dosing, Drug Interactions, and Standard Treatment Guidelines

---

1. Background: Why Atropine?

Critical point: Atropine does NOT reactivate cholinesterase, does NOT reverse nicotinic effects (muscle paralysis, fasciculations, tachycardia), and does NOT cross the blood-brain barrier well enough to fully treat CNS effects at standard doses. It addresses muscarinic toxicity only.

---

2. The Cholinergic Toxidrome (OP Poisoning Presentation)

---

3. Mechanism of Atropine in OP Poisoning

• Atropine competitively blocks M1, M2, M3, M4, and M5 muscarinic receptors
• Priority target: M3 receptors in the airway - relieves bronchospasm and dries bronchorrhea
• Reverses bradycardia via M2 receptor blockade at the SA node
• Reduces GI hypermotility, secretions, urinary incontinence, and miosis
• Does NOT treat fasciculations, paralysis, or nicotinic effects - this requires pralidoxime (2-PAM)
• Atropinization endpoint is clinical, not a fixed dose

---

4. Harrison's 22E: Standard Treatment Guidelines for OP Poisoning

Goals of Treatment (4 pillars per Rosen's/Tintinalli's, consistent with Harrison's framework)

1. Decontamination
2. Supportive care with respiratory stabilization
3. Reversal of acetylcholine excess (atropine)
4. Reversal of toxin binding at cholinesterase (pralidoxime)

---

Step 1: Decontamination

• Remove and bag all contaminated clothing (treat as hazardous waste)
• Wash skin, scalp, hair, fingernails, skin folds, and conjunctivae with copious soap and water (mild detergent preferred)
• Healthcare workers must wear Level C PPE: full-face air purifying mask, chemical-resistant suit, neoprene/nitrile gloves (NOT latex)
• Do not use helicopters for transport of contaminated patients
• Gastric lavage and activated charcoal: no proven benefit for OP ingestion - rapid absorption and profuse vomiting/diarrhea occur early, negating utility
• Equipment (not skin) may be decontaminated with 5% hypochlorite solution

---

Step 2: Supportive Care and Airway Management

• Place on 100% oxygen via non-rebreather mask, cardiac monitor, and pulse oximeter
• Suction excessive secretions (hypersalivation, bronchorrhea, emesis)
• Endotracheal intubation indicated for: coma, seizures, respiratory failure, severe bronchospasm
• Succinylcholine CAUTION: Succinylcholine (1.5 mg/kg) is metabolized by plasma cholinesterase, and in OP poisoning may have a prolonged duration of 4-6 hours. Prefer a non-depolarizing agent not metabolized by cholinesterases - rocuronium 1 mg/kg is preferred per Rosen's.
• Do NOT delay atropine while setting up oxygen

---

Step 3: Atropine - Dosing Protocol

Initial Dose

Harrison's 22E notes atropine is listed among poisons with specific antidotes. The cholinergic antidote is atropine + pralidoxime, targeting the ACh excess and cholinesterase regeneration respectively.

Titration Protocol

• Double the dose every 5 minutes until adequate atropinization is achieved
• No maximum dose - very large cumulative doses (100-1000 mg over hours) may be required in severe poisoning

Endpoint of Atropinization (NOT pupil dilation or tachycardia alone)

Never titrate atropine to pupil size or dry skin - miosis and diaphoresis can persist due to nicotinic/local effects; using these as endpoints leads to dangerous overdosing.

Maintenance Infusion

• Continuous IV infusion at 10-20% of the total loading dose per hour
• Typical adult infusion rates: 0.4 to 4 mg/hour IV
• Adjust to maintain clear lung fields and avoid atropine toxicity

Signs of Atropine Toxicity (over-atropinization) - AVOID these:

• Absent bowel sounds
• Hyperthermia
• Delirium / agitation
• Urinary retention
• Severe tachycardia (HR >140) without clinical need

---

Step 4: Pralidoxime (2-PAM, Protopam) - The Oxime

Dosing (per Tintinalli's Table 201-3)

• Give as early as possible - before aging occurs
• Soman (nerve agent) ages within minutes, making pralidoxime less effective
• Pralidoxime may still offer some benefit 24-48 hours after exposure
• Pralidoxime does NOT enter the CNS and cannot reverse central effects alone
• In combination product (Duodote/ATNAA): used in mass casualty/nerve agent scenarios

Pralidoxime Cautions

• Can cause muscle weakness in overdose
• Administer slowly to avoid hypertension, tachycardia, dizziness, blurred vision
• Not indicated for carbamate poisoning - carbamates spontaneously reactivate AChE and pralidoxime may worsen carbamate toxicity (controversial - varies by carbamate)

---

Step 5: Seizure Management

• Benzodiazepines IV are first-line for seizures (diazepam, lorazepam, midazolam)
• Phenytoin is less effective for OP-induced seizures (GABA-ergic mechanism preferred)
• Seizures may be refractory and require high-dose benzodiazepines

---

5. Drug Interactions with Atropine in OP Poisoning

A. Interactions Relevant to OP Poisoning Management

B. Medications that falsely alter cholinesterase lab values (affecting OP diagnosis, not atropine directly)

• Succinylcholine, codeine, morphine: Depress plasma butyrylcholinesterase levels
• Hemoglobinopathies, pernicious anemia, antimalarial drugs: Lower RBC AChE readings
• Pregnancy, liver disease, malnutrition, low albumin: Lower pseudocholinesterase

C. Harrison's 22E Note on Cholinomimetics Post-Antibiotic Therapy

---

6. Special Situations

Nerve Agents (Chemical Warfare)

• Sarin, soman, VX: very rapid aging
• Autoinjectors (ATNAA/Duodote): pre-loaded atropine + pralidoxime for military/field use
• Soman ages within minutes - pralidoxime efficacy is severely limited; atropine becomes the mainstay
• Benzodiazepines co-administered for seizure prophylaxis in mass casualty scenarios

Pediatric Considerations

• Children have lower baseline cholinesterase levels and smaller body size - more susceptible to toxicity
• Atropine: start 0.05 mg/kg IV, titrate to same endpoints
• Pralidoxime: 30 mg/kg up to 1 g IV

Intermediate Syndrome

• Occurs 24-96 hours after acute poisoning resolves
• Proximal limb weakness, neck flexor weakness, cranial nerve palsies, respiratory failure
• NOT prevented by atropine or pralidoxime
• Managed with ventilatory support; typically resolves in 1-2 weeks
• NOT seen with nerve agents

Organophosphate-Induced Delayed Neuropathy (OPIDN)

• Peripheral sensorimotor axonopathy developing weeks after exposure
• Cognitive dysfunction, autonomic dysfunction, extrapyramidal signs
• Chronic agricultural workers at risk

---

7. Summary Treatment Algorithm (Harrison's/Tintinalli Framework)

OP Poisoning Suspected
        ↓
1. DECONTAMINATE (PPE for staff, soap + water for patient)
        ↓
2. AIRWAY + O2 (Intubate if needed; use rocuronium, avoid succinylcholine)
        ↓
3. ATROPINE IV
   Adults: 2-4 mg IV bolus → double q5 min → until lungs clear
   Children: 0.05 mg/kg IV → titrate
   Then maintenance infusion 0.4-4 mg/hr
        ↓
4. PRALIDOXIME IV (as early as possible)
   Adults: 30 mg/kg (up to 2g) over 5-10 min → 8 mg/kg/hr x 24-48 hr
        ↓
5. SEIZURES: Benzodiazepines IV (diazepam/lorazepam)
        ↓
6. MONITOR: Cardiac, SpO2, glucose, electrolytes, acid-base
   Watch for intermediate syndrome at 24-96 hrs

---

Key Points to Remember

• Atropine is titrated to secretions (dry lungs), not to pupil size or heart rate
• Very large doses may be needed; do not under-dose atropine
• Pralidoxime must be given early before aging; works on NMJ, not muscarinic
• Succinylcholine is dangerous - prefer rocuronium for intubation
• Benzodiazepines are essential for seizures
• Activated charcoal and gastric lavage have no proven benefit in OP ingestion
• Always use PPE - secondary contamination of healthcare workers is a real risk
• Lab cholinesterase levels confirm diagnosis but must never delay treatment

---

• Harrison's Principles of Internal Medicine 22E (2025), Tables 470-1 through 470-4, Chapter on Poisoning
• Tintinalli's Emergency Medicine, Chapter 201, Table 201-3: Treatment for Organophosphate Poisoning
• Rosen's Emergency Medicine, Chapter 152: Pesticide Poisoning
• Katzung's Basic and Clinical Pharmacology 16th Ed, Cholinesterase Inhibitors section
• Harriet Lane Handbook 23rd Ed, Pralidoxime + Atropine entry

---

Pralidoxime in Carbamate vs. Organophosphate Poisoning: Latest Clinical Guidelines and Evidence

---

Overview: Why the Debate Exists

---

Part 1: Organophosphate (OP) Poisoning - Pralidoxime

Mechanism of Action (in OP)

• OPs phosphorylate the serine-OH at the AChE active site
• Pralidoxime's oxime group (=NOH) has high affinity for the phosphorus atom, competing with serine-OH
• It hydrolyzes the OP-enzyme conjugate if administered before "aging"
• Aging = loss of one alkyl group from the OP-AChE complex → makes it irreversible

Per Katzung (16th Ed): "Pralidoxime is most effective in regenerating the cholinesterase associated with skeletal muscle neuromuscular junctions." It does NOT cross the BBB (quaternary ammonium charge prevents CNS entry), so CNS effects remain unaddressed.

Critical Limitation: Efficacy by OP Subclass

• Dimethyl OPs (e.g., dimethoate, methamidophos - common in Asia/Sri Lanka): age rapidly; pralidoxime often of limited benefit
• Diethyl OPs (e.g., chlorpyrifos, diazinon): longer aging window; better candidates for oxime therapy
• This subclass dependency explains much of the conflicting clinical trial data

---

Evidence Base: Key Trials and Reviews

Cochrane Systematic Review (Buckley, Eddleston et al., 2011 - PMID 21328273) - Tier 1

"Current evidence is insufficient to indicate whether oximes are harmful or beneficial. The WHO recommended regimen (30 mg/kg bolus + 8 mg/kg/hr infusion) is NOT supported. Further RCTs are required."

• Results were highly disparate across trials - ranging from benefit to harm
• Only one RCT used WHO-recommended doses vs. placebo - showed no clinical benefit and a trend toward harm across all subgroups
• Despite biochemical evidence of AChE reactivation in blood, this did not translate to clinical benefit
• Problems identified: imbalanced baselines, wide dose variation, delays to treatment, failure to account for OP type

2025 Meta-Analysis (Wang & Wang, Int Emerg Nurs - PMID 40714568) - Tier 2 - Most Recent

"Compared with atropine alone, the atropine plus pralidoxime group showed a significantly higher risk of mortality (P = 0.020) and a longer length of stay (P < 0.001), while no significant differences were observed in the need for mechanical ventilation or its duration."

• Hemopurification (combined with atropine) significantly reduced mortality (P = 0.020) and LOS - emerging as a promising adjunct
• Sodium bicarbonate significantly reduced LOS
• Pralidoxime's unfavorable signal in this analysis adds to growing concern about routine use

Eddleston Lancet RCT (2005, PMID 16243090)

• Prospective cohort study from Sri Lanka
• Showed significant differences in outcome depending on which OP compound was ingested
• Emphasizes that pralidoxime efficacy is compound-specific, not class-wide

Pawar et al., Lancet 2006

• Continuous pralidoxime infusion vs. repeated bolus injection
• Continuous infusion showed improved survival in moderately severe OP poisoning compared to intermittent boluses
• Supports the infusion-based dosing regimen if pralidoxime is to be used

de Silva et al., Lancet 1992

• Atropine alone appeared as effective as atropine + pralidoxime in acute OP poisoning
• One of the earliest signals against routine pralidoxime use

---

Current Guideline Positions on Pralidoxime in OP Poisoning

2023 American Heart Association (AHA) Focused Update

• Recommends atropine immediately for bronchospasm, bronchorrhea, seizures, or significant bradycardia from severe OP poisoning
• For oximes: "In cases of significant OP poisoning (particularly with muscle fasciculations, weakness, or paralysis), consideration can be given to early administration of oximes such as pralidoxime"
• Explicit caveat: oximes "are not universally effective"
• Low-dose (1-2 g slow IV) is the current preference; high-dose pralidoxime is associated with more complications

WHO Recommended Regimen (referenced in Tintinalli's)

• 30 mg/kg IV bolus → 8 mg/kg/hr continuous infusion
• Continued for 24-48 hours; titrate against clinical response and cholinesterase recovery
• Per Tintinalli's: "Current evidence is inadequate to show that oximes reduce mortality or the complication rate in acute organophosphate poisoning"

Tintinalli's Emergency Medicine (current edition)

"Pralidoxime is not recommended for asymptomatic patients or for patients with known carbamate exposures presenting with minimal symptoms."

• Give if the patient has muscle fasciculations, weakness, or paralysis (nicotinic effects)
• Give early - before aging completes (within 24-48 hours of exposure, though benefit diminishes rapidly)
• Do NOT withhold for fear of futility in severe/symptomatic OP poisoning

2024 - "Pralidoxime Is No Longer Fit for Purpose" (UK)

---

Dosing (Current Standard - for symptomatic OP poisoning)

• Rapid IV push: hypertension, tachycardia, dizziness, muscle weakness - always infuse slowly
• Overdose: can cause neuromuscular weakness (mimics or worsens nicotinic effects)
• Paradoxical cholinergic effects at high doses

---

Part 2: Carbamate Poisoning - Pralidoxime is NOT Recommended

Pathophysiology Difference (The Key)

"The carbamate-binding half-life to cholinesterase is approximately 30 minutes, and irreversible binding does not occur; therefore, there is little need for pralidoxime."

"Administration of pralidoxime may not be necessary in cases of carbamate insecticide poisoning because carbamylated cholinesterase spontaneously reactivates within [hours]."

"Pralidoxime is NOT recommended for the reversal of inhibition of acetylcholinesterase by carbamate inhibitors."

---

The Carbaryl Problem (Critical Safety Issue)

• Proposed mechanism: pralidoxime itself may weakly inhibit cholinesterase when the enzyme is not phosphorylated, or it may form a toxic complex with carbaryl
• Result: worsened cholinergic crisis

"Pralidoxime should be AVOIDED in known single-agent carbaryl poisonings."

---

Treatment Algorithm for Carbamate Poisoning

1. Atropine - same titration as OP (to clear lungs, HR >80, SBP >80 mmHg)
2. Atropine alone is usually sufficient while awaiting spontaneous AChE reactivation
3. Most patients recover within 6-24 hours (therapy rarely needed beyond 6-12 hours)
4. Pralidoxime: avoid unless:
   • Mixed OP + carbamate exposure
   • Unknown insecticide type
   • Severe, life-threatening presentation where OP cannot be excluded

---

Part 3: Head-to-Head Comparison Table

---

Summary of Current Guideline Positions

---

Bottom Line for Clinical Practice

• Atropine remains the undisputed cornerstone - titrate aggressively to pulmonary secretions
• Pralidoxime should be considered in significant OP poisoning, particularly when nicotinic features (fasciculations, paralysis) are prominent
• Give early (before aging); efficacy is OP compound-specific
• Do not use high doses - administer slowly; continuous infusion preferred over bolus
• The 2025 meta-analysis and Cochrane 2011 cast doubt on routine use, but expert consensus (AHA 2023) still supports selective use
• Consider hemopurification as an emerging adjunct based on 2025 meta-analysis evidence

• Atropine is the antidote - usually all that is needed
• Avoid pralidoxime, particularly in known carbaryl exposure
• If agent is unknown or mixed OP + carbamate exposure is possible, pralidoxime is reasonable pending clarification
• Most patients recover within 24 hours with atropine alone

---

• Cochrane: Oximes for acute OP poisoning, PMID 21328273 (Buckley, Eddleston et al. 2011)
• Meta-analysis: Emergency adjunctive therapy for OP poisoning, PMID 40714568 (Wang & Wang 2025) - most recent evidence
• AHA 2023 Focused Update on Life-Threatening Toxicity (Lavonas et al., Circulation 2023)
• Tintinalli's Emergency Medicine, Chapters 201 (OP) and Carbamates section
• Katzung's Basic and Clinical Pharmacology, 16th Ed, Chapter on Pralidoxime
• Tietz Textbook of Laboratory Medicine, 7th Ed, Organophosphate and Carbamate Compounds

---

Sarin, Soman, VX, and Tabun: Complete Guide

---

1. Historical Background

• The G-agents (GA, GB, GD) were developed in Nazi Germany, initially as insecticides, then recognized as devastating weapons
• VX was developed by British scientists and was found to be 20× more potent than the G-series compounds (per Katzung)
• All were later manufactured in the United States and USSR during the Cold War
• They are classified as Weapons of Mass Destruction (WMD) and are banned under the Chemical Weapons Convention (1993)

---

2. Chemical Classification

• Tabun (GA): ethyl dimethylphosphoramidocyanidate - contains a cyanide group (unique)
• Sarin (GB): isopropyl methylphosphonofluoridate - contains a fluoride leaving group
• Soman (GD): pinacolyl methylphosphonofluoridate - contains a fluoride leaving group

• VX: O-ethyl S-[2-(diisopropylamino)ethyl] methylphosphonothioate - sulfur-containing, highly persistent

---

3. Physical Properties Comparison

Because vapors are heavier than air, all agents accumulate in low-lying areas, basements, trenches, and downwind/downhill locations - a critical tactical and rescue consideration.

---

4. Mechanism of Toxicity (All Four Agents - Same Core)

Nerve Agent + AChE → Phosphorylated-AChE (INACTIVE)
                               ↓
              Acetylcholine accumulates in ALL synapses
                               ↓
    Muscarinic + Nicotinic + CNS receptors all overstimulated
                               ↓
                  Cholinergic crisis → DEATH

1. Bronchospasm + bronchorrhea (airway fills with secretions)
2. Respiratory muscle paralysis (nicotinic NMJ effect)
3. CNS respiratory center depression

---

5. Clinical Presentation (DUMBBELS / SLUDGE + Nicotinic + CNS)

Muscarinic Effects (SLUDGE/DUMBBELS):

• Salivation, Lacrimation, Urination, Defecation, GI cramps, Emesis
• Miosis (pinpoint pupils) - often the first sign with vapor exposure
• Bronchorrhea, bronchospasm, bradycardia, hypotension

Nicotinic Effects (NMJ and ganglia):

• Muscle fasciculations → weakness → flaccid paralysis
• Tachycardia (may mask bradycardia)
• Hypertension, pallor, sweating

CNS Effects:

• Anxiety, agitation, confusion
• Seizures (status epilepticus common in severe exposure)
• Loss of consciousness → coma
• Central respiratory depression

Miosis and rhinorrhea are the most common early findings after vapor exposure. With skin absorption (especially VX), miosis may be absent initially.

---

6. Each Agent in Detail

---

Tabun (GA) - "The First"

• First nerve agent ever synthesized (1936, Gerhard Schrader)
• Unique among the four: contains a dimethylamino group and a cyanide (CN) moiety rather than a fluoride leaving group
• Historically stockpiled by Iraq (used in Iran-Iraq War, 1980s)
• Aging half-life: ~14 hours - relatively good window for pralidoxime
• Slightly fruity/almond odor (but unreliable as a warning)
• Pralidoxime efficacy: Limited - the dimethylamino group makes the aged complex difficult to reactivate with standard oximes; obidoxime performs better against tabun
• Medium volatility - both vapor and liquid hazard

---

Sarin (GB) - "The Most Volatile"

• Most volatile of all nerve agents - evaporates rapidly at room temperature
• Therefore primarily a vapor/inhalation hazard; skin absorption from vapor is possible
• Odorless - no warning before toxic exposure
• Used in the 1995 Tokyo subway attack by Aum Shinrikyo (13 killed, ~50 severely injured, ~1000 affected)
• Used in the 2013 Ghouta chemical attack in Syria (1,400+ killed)
• Aging half-life: ~3-5 hours - reasonable window for pralidoxime if given promptly
• LCt50 (lethal concentration × time for 50% of exposed population): ~35 mg·min/m³ (inhalation)
• Most studied agent clinically due to mass casualty events

---

Soman (GD) - "The Fastest Ager"

• Clinically the most dangerous agent in terms of pralidoxime window
• Aging half-life: 2-6 MINUTES - by the time a patient reaches medical care, AChE is already fully aged and irreversibly inhibited
• This renders pralidoxime essentially useless for soman poisoning
• Contains a pinacolyl group that undergoes rapid dealkylation (aging mechanism)
• Slightly fruity or camphor-like odor (unreliable)
• Moderate volatility - both vapor and skin hazard
• Pre-treatment with pyridostigmine (reversible AChE inhibitor used prophylactically in military) is specifically designed for soman, as it occupies AChE temporarily, protecting it from permanent soman-binding
• Higher doses required to kill vs. VX but still extremely toxic

---

VX - "The Persistent Killer"

• Most potent nerve agent known (20× more potent than G-series per Katzung)
• Least volatile - an oily, amber-colored liquid that evaporates extremely slowly
• Therefore primarily a skin contact hazard (percutaneous route is the main threat)
• Odorless - no warning
• Skin LD50: ~10 mg for a 70 kg adult (a droplet the size of a pinhead can be lethal)
• Persistence: can contaminate terrain, equipment, and clothing for days to weeks - major decontamination challenge
• Used in the assassination of Kim Jong-nam (Kuala Lumpur airport, 2017)
• Iraq used VX against the Kurdish population (Halabja, 1988, along with tabun and mustard)
• Aging half-life: ~48 hours - best window for pralidoxime among the four agents
• Absorption route matters: vapor → primarily pulmonary; liquid contact → percutaneous
  • Small skin exposure: delayed onset (30 min to hours), localized sweating/fasciculations first
  • Large skin exposure: rapid systemic cholinergic crisis

---

7. Aging Timeline Summary (Critical for Pralidoxime)

Soman (GD)   ←→  2-6 min   [Pralidoxime USELESS - treat with atropine + BZDs only]
Sarin (GB)   ←→  3-5 hr    [Pralidoxime EFFECTIVE if given PROMPTLY]
Tabun (GA)   ←→  ~14 hr    [Pralidoxime LIMITED - obidoxime preferred]
VX           ←→  ~48 hr    [Pralidoxime MOST EFFECTIVE window among the four]

---

8. Treatment (All Four Agents - Same Protocol, Different Urgency)

Step 1: Decontamination (CRITICAL - do this BEFORE entering hospital)

• Remove all clothing (destroys 80% of external contamination)
• Flush skin with copious soap and water (low pressure to avoid skin abrasion)
• PPE Level B minimum for first responders; Level C (PAPR + chemical-resistant suit) for ED personnel
• Do NOT transport by helicopter (contamination risk)
• Isolate runoff water as hazardous waste

Step 2: Airway + Oxygen

• 100% O2 via non-rebreather mask
• Intubate early for CNS depression, seizures, or severe bronchorrhea
• Succinylcholine: prolonged duration (hours) due to inhibited plasma cholinesterase - prefer rocuronium 1.2 mg/kg

Step 3: Atropine - The Mainstay

• Adults: 2-4 mg IV bolus; double every 5 minutes until lungs clear
• Children: 0.05 mg/kg IV
• Target: clear chest, HR >80, SBP >80 mmHg (NOT pupil dilation)
• Hundreds of mg may be required in massive exposure
• Maintain with infusion at 10-20% of loading dose/hour

Step 4: Pralidoxime - Agent-Dependent Urgency

• Dose: 30 mg/kg IV (max 2g) over 15-30 min → 8 mg/kg/hr infusion × 24-48 hr
• Military autoinjectors (ATNAA/Duodote): atropine 2.1 mg + pralidoxime 600 mg IM

Step 5: Benzodiazepines

• Diazepam 5-10 mg IV or lorazepam 2-4 mg IV for seizures
• Diazepam 10 mg IM is in military autoinjector kits (Convulsant Antidote for Nerve Agents - CANA)
• Phenobarbital as second-line for refractory seizures

Step 6: Other / Emerging

• Scopolamine (anticholinergic) has been used as adjunct in some protocols
• Pyridostigmine prophylaxis (30 mg PO q8h before exposure) for soman - only effective as pre-exposure prophylaxis, not treatment
• Bioscavengers: experimental use of butyrylcholinesterase under research
• Magnesium sulfate: some evidence as adjunct; not yet standard

---

9. Real-World Use: Notable Incidents

---

10. Quick Summary Table

---

• Rosen's Emergency Medicine, Chapter 55 (Chemical Agents / Weapons of Mass Destruction)
• Katzung's Basic and Clinical Pharmacology, 16th Ed, Organophosphorus (OP) Pesticides section
• Tintinalli's Emergency Medicine, Chapter 201 (Cholinesterase Inhibitors)
• ATSDR Medical Management Guidelines for GA/GB/GD/VX
• WHO EMRO Nerve Gas Fact Sheet
• Johns Hopkins Center for Health Security - Nerve Agents

---

Complete Teaching Guide: OP Poisoning, Intermediate Syndrome, and Atropine Toxicity

---

PART 1: PATHOPHYSIOLOGY OF ORGANOPHOSPHORUS (OP) POISONING

1.1 The Normal Cholinergic Synapse (Baseline)

Presynaptic neuron
        ↓
  ACh synthesized (choline acetyltransferase)
        ↓
  ACh stored in vesicles
        ↓
  Action potential → ACh released into synaptic cleft
        ↓
  ACh binds Muscarinic (M) or Nicotinic (N) receptors
        ↓
  Physiologic effect (contraction, secretion, etc.)
        ↓
  AChE degrades ACh → Choline + Acetate
        ↓
  Choline recycled back into presynaptic terminal
  Signal TERMINATES

• Nerve synapses (cholinergic)
• Neuromuscular junctions (NMJ)
• Red blood cell membranes
• Brain tissue

• Plasma / serum
• Liver, pancreas
• Heart, brain

---

1.2 What OPs Do: The Molecular Attack

OP compound
     ↓
Enters body (inhalation / skin / gut)
     ↓
Phosphorylates the SERINE-OH at AChE active site
     ↓
OP-AChE covalent complex = DEAD ENZYME
     ↓
AChE cannot bind or hydrolyze ACh anymore
     ↓
ACh accumulates at ALL cholinergic synapses
     ↓
CHOLINERGIC CRISIS

---

1.3 "Aging" - The Point of No Return

OP-AChE complex (freshly formed)
            ↓ (time passes - minutes to days)
Dealkylation: one alkyl group falls off the phosphorus
            ↓
AGED complex = permanently irreversible
            ↓
Pralidoxime CANNOT break this bond anymore
            ↓
Only new AChE synthesis restores function
   (RBC AChE: up to 120 days to fully recover)
   (Plasma BuChE: 28-42 days)

---

1.4 Why ACh Accumulation is Lethal: Receptor Map

A. Muscarinic Receptors (Parasympathetic postganglionic)

B. Nicotinic Receptors - Neuromuscular Junction (NMJ)

Phase 1 (early): ACh excess → continuous NMJ depolarization
                              → Muscle FASCICULATIONS
                              ↓ (ongoing depolarization)
Phase 2 (late): Depolarization block / receptor desensitization
                              → Muscle WEAKNESS → PARALYSIS

C. Nicotinic Receptors - Autonomic Ganglia & Adrenal Medulla

• Sympathetic ganglia stimulation → tachycardia, hypertension, mydriasis, pallor, sweating
• Adrenal medulla stimulation → catecholamine surge
• These nicotinic effects often counteract the muscarinic bradycardia/hypotension, creating a mixed autonomic picture

D. CNS Receptors

• M1/M4 receptor excess in limbic system, cortex, reticular formation
• Anxiety → confusion → seizures (status epilepticus) → coma
• CNS respiratory center depression adds to peripheral respiratory failure
• OPs that cross the BBB (lipophilic ones like chlorpyrifos, parathion) = more CNS toxicity

---

1.5 Why Do Patients Die?

1. BRONCHORRHEA: Airways fill with secretions (M3 effect)
         +
2. BRONCHOSPASM: Airway smooth muscle contracts (M3 effect)
         +
3. RESPIRATORY MUSCLE PARALYSIS: Diaphragm/intercostals fail (Nicotinic NMJ)
         +
4. CNS RESPIRATORY CENTER DEPRESSION (central M receptors)
         ↓
         ↓
   ASPHYXIA → DEATH

---

1.6 The Four Clinical Syndromes of OP Poisoning

---

PART 2: INTERMEDIATE SYNDROME (IMS)

2.1 Definition and Timing

TIMELINE OF OP POISONING:

Day 0     Day 1-4          Day 7-21         Weeks-Months
  |           |                |                  |
Acute    INTERMEDIATE      DELAYED           CHRONIC
Crisis    SYNDROME        NEUROPATHY        EFFECTS
(M + N)   (N only)        (OPIDP)

• Occurs in up to 40% of severely poisoned patients (Tintinalli's)
• Most common with lipophilic OPs that redistribute from fat stores: fenthion, dimethoate, parathion, chlorpyrifos, malathion
• NOT seen with nerve agents (sarin, soman, VX, tabun)
• CAN occur with carbamates (Tintinalli's) - though less common

---

2.2 Pathophysiology of IMS - Step by Step

Step 1: Persistent Cholinesterase Inhibition (The Root Cause)

Lipophilic OP compounds
        ↓
Initially treated → cholinergic crisis resolved
        ↓
BUT: OP remains sequestered in ADIPOSE TISSUE
        ↓
Slow redistribution from fat → ongoing plasma release
        ↓
Continued AChE inhibition at the NMJ (days later)
        ↓
ACh continues to accumulate at nicotinic NMJ synapses

Step 2: Nicotinic Receptor Overstimulation → Desensitization

Persistent ACh excess at NMJ
        ↓
Phase 1: Continuous nicotinic receptor activation
        ↓
Phase 2: Receptor DESENSITIZATION (conformational change)
         - Receptor remains in non-conducting state
         - Does NOT respond to further ACh
        ↓
Post-junctional failure of neuromuscular transmission
        ↓
PROGRESSIVE WEAKNESS WITHOUT FASCICULATIONS

Step 3: Electrophysiological Correlate

• Repetitive nerve stimulation: decremental response (like myasthenia gravis)
• Single-fiber EMG: increased jitter and blocking
• This confirms the post-synaptic (or NMJ) failure of transmission
• Motor nerve conduction velocity is usually normal (distinguishes from OPIDP)

Step 4: Selective Muscle Vulnerability

Most vulnerable → Least vulnerable:

Neck flexors           [Highly affected - early sign]
       ↓
Cranial nerve muscles  [Facial weakness, dysphagia, ophthalmoplegia]
       ↓
Proximal limb muscles  [Shoulder, hip girdle weakness]
       ↓
Respiratory muscles    [DIAPHRAGM - the killer]
       ↓
Distal limb muscles    [Relatively spared]

---

2.3 Clinical Features of IMS

Characteristic Presentation:

• Patient has recovered from acute cholinergic crisis (no more SLUDGE signs)
• No miosis, no bradycardia, no bronchorrhea
• Then 24-96 hours later, new-onset weakness develops:

What Makes It Dangerous:

• Patient appears to be recovering → family/staff not vigilant
• Silent respiratory failure develops - patient goes hypoxic before oxygenation is noticed
• In resource-limited settings, IMS is frequently fatal

---

2.4 Diagnosis of IMS

1. History of OP exposure
2. Prior resolution of acute cholinergic crisis
3. New proximal weakness + cranial nerve signs at 24-96 hours
4. Absence of cholinergic features

• EMG/NCS: decremental response on repetitive nerve stimulation
• RBC AChE: still significantly depressed (confirms ongoing inhibition)
• SpO2/ABG: monitor for silent hypoxia
• Chest X-ray: aspiration pneumonia common
• Spirometry/FVC: declining FVC signals impending respiratory failure (monitor serially)

• Myasthenia gravis (no OP exposure history)
• Guillain-Barré syndrome (ascending vs. proximal pattern; CSF changes)
• Botulism (descending paralysis, constipation)
• Over-atropinization (but would have anticholinergic signs)

---

2.5 Treatment of IMS

• Resolves within 7-14 days (up to 3 weeks) with ventilatory support
• Full recovery of muscle function expected
• Death occurs only if ventilatory support is unavailable or delayed

---

PART 3: PATHOPHYSIOLOGY OF ATROPINE POISONING

3.1 Normal Role of Atropine

---

3.2 Dose-Response Relationship (Barash's Clinical Anesthesia Table)

---

3.3 Pathophysiology of Atropine Poisoning (Peripheral Anticholinergic Effects)

The 5-organ-system blocking pattern:

Atropine
    ↓
M Receptor Blockade
    ↓
No ACh signal at:

1. HEART (M2)
   SA node: removal of vagal brake → TACHYCARDIA
   AV node: decreased conduction delay

2. AIRWAYS (M3)
   Smooth muscle: BRONCHODILATION
   Glands: DECREASED secretions → DRY AIRWAYS

3. EYES (M3)
   Iris sphincter blocked: MYDRIASIS (dilated pupils)
   Ciliary muscle blocked: CYCLOPLEGIA (cannot accommodate)
   → Blurred vision, photophobia

4. SKIN & GLANDS (M3)
   Sweat glands blocked → ANHIDROSIS (cannot sweat)
   → Heat cannot dissipate → HYPERTHERMIA
   Skin becomes DRY, HOT, FLUSHED (vasodilation compensating)

5. GI + URINARY (M3)
   GI motility reduced → ILEUS, constipation
   Urinary detrusor blocked → URINARY RETENTION

"Dry as a bone - Red as a beet - Blind as a bat - Hot as a hare - Mad as a hatter"

---

3.4 Pathophysiology of Atropine-Induced Psychosis (Central Anticholinergic Syndrome)

Why the Brain is Uniquely Vulnerable:

• Cerebral cortex (especially frontal and parietal lobes)
• Limbic system (hippocampus, amygdala)
• Basal ganglia
• Reticular activating system (RAS)
• Thalamus

• Attention and arousal (via basal forebrain-cortical cholinergic projection)
• Memory encoding (hippocampal M1 receptors)
• Reality testing and perception (limbic-cortical circuit)
• REM sleep gating

Mechanism of Central Anticholinergic Psychosis:

Atropine (lipid-soluble tertiary amine)
        ↓
Crosses blood-brain barrier freely
        ↓
Blocks M1 + M4 receptors in:
        ↓

CORTEX (frontal):
  Loss of executive function → disorganized thinking
  Disrupted reality monitoring → hallucinations

LIMBIC SYSTEM (hippocampus):
  M1 block → impaired cholinergic-glutamate balance
  Memory consolidation fails → disorientation
  Amygdala dysregulation → fear, agitation, paranoia

RETICULAR ACTIVATING SYSTEM:
  Impaired arousal regulation → hyperarousal OR stupor
  Sleep-wake cycle disruption → "waking dream" state

BASAL GANGLIA:
  Dopamine-acetylcholine imbalance (ACh normally inhibits DA)
  M4 block → relative DA excess → psychomotor agitation

Clinical Features of Central Anticholinergic Syndrome (CAS):

The "Waking Dream" Quality:

How to Distinguish Atropine Psychosis from Cholinergic Psychosis (in OP Poisoning Management):

Clinical rule: If a patient being treated for OP poisoning develops tachycardia, hot dry skin, absent bowel sounds, and dilated pupils with psychosis - this is over-atropinization, not more OP poisoning. STOP atropine. Treat with physostigmine.

---

3.5 Full Treatment Guidelines for Atropine Poisoning / Anticholinergic Syndrome

Step 1: Assess Severity

Step 2: Supportive Measures

• Airway: Secure early if psychosis is severe (aspiration risk from agitation)
• Cardiac monitoring: Continuous ECG (tachyarrhythmias)
• IV access: Fluid resuscitation
• Temperature control: External cooling (ice packs, cooling blankets) - hyperthermia is the primary killer in anticholinergic toxicity; temperature >40°C requires aggressive cooling
• Foley catheter: For urinary retention
• Dark, quiet environment: Reduces agitation from sensory overload (photophobia)
• Restraints/padded environment: Protect agitated patient from injury
• Activated charcoal (1 g/kg): If recent oral ingestion (within 1-2 hours) AND airway protected

Step 3: Benzodiazepines for Agitation/Seizures

• Diazepam 5-10 mg IV or lorazepam 1-2 mg IV for agitation
• Avoid:
  • Phenothiazines (chlorpromazine, haloperidol): have their own anticholinergic properties - will worsen syndrome
  • Physostigmine in patients with cardiac conduction disease (risk of bradyarrhythmia)

Step 4: Physostigmine - The Antidote

• Crosses the BBB (unlike neostigmine or pyridostigmine - quaternary amines)
• Inhibits AChE centrally and peripherally
• Increases ACh concentrations in CNS → reverses central anticholinergic syndrome
• Is the only antidote that treats both central and peripheral anticholinergic toxicity

Indications for Physostigmine:

• Severe agitation or psychosis not controlled by benzodiazepines
• Hemodynamically significant tachydysrhythmia
• Refractory or recurrent seizures
• Coma from anticholinergic toxicity
• When diagnosis of anticholinergic syndrome is confirmed (peripheral signs present)

Dose:

• Adults: 1-2 mg slow IV (over 5 minutes) - never rapid push
• Children: 0.02 mg/kg IV (max 0.5 mg), repeat q5-10 min as needed
• Onset within 5-15 minutes
• Duration: 30-60 minutes (shorter than atropine's duration)
• May require repeat dosing as CAS recurs

Contraindications to Physostigmine:

• Asthma (can precipitate severe bronchospasm)
• Cardiac conduction defects (risk of heart block, asystole)
• GI or urinary obstruction
• Peripheral vascular disease
• TCA (tricyclic antidepressant) overdose - must exclude this before giving physostigmine (TCAs cause QRS widening; cholinergic excess from physostigmine can cause fatal arrhythmia here)
• NEVER give in OP poisoning (will worsen cholinergic crisis by further inhibiting AChE)

If Physostigmine Causes Cholinergic Excess:

• Give atropine 0.5 mg for every 1 mg of physostigmine administered
• This reverses any physostigmine-induced cholinergic overdose

Step 5: Gastric Decontamination

• Activated charcoal: useful within 1-2 hours of ingestion (adequate airway essential)
• Jimson weed (Datura stramonium) ingestion with large seed quantity: whole-bowel irrigation is recommended due to delayed release from the gut
• Gastric lavage: rarely needed; only for massive recent ingestions
• Do NOT induce emesis (aspiration risk in altered consciousness)

Step 6: Enhanced Elimination

• Forced diuresis: no proven benefit
• Hemodialysis: not effective (atropine is highly protein-bound and large volume of distribution)
• Hemoperfusion: limited evidence

Step 7: Emerging Options (2023-2024)

• Rivastigmine (transdermal or oral): A longer-acting cholinesterase inhibitor being used for refractory anticholinergic delirium as a bridge when physostigmine requires repeated dosing
  • Chiew et al., Clin Toxicol 2024 - case series showing benefit
  • Transdermal rivastigmine offers sustained effect vs. short-acting physostigmine
• Donepezil: Another AChE inhibitor with CNS penetration; limited emergency data but used in some refractory cases

---

3.6 Atropine-Induced Psychosis in OP Management: The Clinical Trap

• Dry skin, tachycardia, absent bowel sounds, mydriasis → Option B (over-atropinization)
• Wet skin, bradycardia, increased secretions, miosis → Option A (still cholinergic)

---

Integrated Timeline Summary

HOUR 0: OP EXPOSURE
     ↓
HOURS 0-24: ACUTE CHOLINERGIC CRISIS
   • SLUDGE/DUMBELS (muscarinic)
   • Fasciculations → paralysis (nicotinic NMJ)
   • Seizures, coma (CNS)
   TREAT: Atropine + Pralidoxime + BZDs
     ↓
     ↓ ← RISK: Over-atropinization during this phase
         → Anticholinergic syndrome / psychosis
         → STOP atropine, cool patient, physostigmine if needed
     ↓
DAYS 1-5: INTERMEDIATE SYNDROME (IMS)
   • Acute crisis resolved, NO cholinergic signs
   • Proximal weakness, neck flexion weakness
   • Cranial nerve palsies, dysphagia
   • RESPIRATORY FAILURE (silent)
   TREAT: Ventilatory support only; no antidote
     ↓
WEEKS 2-3: DELAYED POLYNEUROPATHY (OPIDP)
   • Distal sensorimotor neuropathy
   • Ascending weakness (GBS-like)
   • Target: NTE enzyme (not AChE)
   TREAT: Supportive; no specific antidote
     ↓
WEEKS-MONTHS: CHRONIC NEUROPSYCHIATRIC EFFECTS
   • Cognitive impairment, depression
   • Autonomic neuropathy
   • Extrapyramidal signs
   TREAT: Neuropsychiatric rehabilitation

---

• Tintinalli's Emergency Medicine, Chapter 201 (Organophosphates, Carbamates)
• Katzung's Basic and Clinical Pharmacology, 16th Ed, Organophosphorus Pesticides and Cholinesterase Inhibitors
• Barash's Clinical Anesthesia, 9th Ed, Muscarinic Antagonist Toxicity (Table 13-3)
• Bradley & Daroff's Neurology in Clinical Practice, Organophosphates and Anticholinergics
• Rosen's Emergency Medicine, Chapter 152 (Pesticide Poisoning)
• StatPearls - Atropine (NCBI Bookshelf)
• Kaplan & Sadock's Synopsis of Psychiatry, Drug-Induced Syndromes Table

---

The Complete Autonomic Pharmacology Master Guide

---

THE BIG PICTURE FIRST

NERVOUS SYSTEM
├── Central Nervous System (CNS) - Brain + Spinal Cord
└── Peripheral Nervous System
    ├── SOMATIC (voluntary) → Controls skeletal muscle
    └── AUTONOMIC (involuntary) → Controls heart, glands, smooth muscle
        ├── SYMPATHETIC ("fight or flight") 🦁
        └── PARASYMPATHETIC ("rest and digest") 🌿

1. Acetylcholine (ACh) - the cholinergic transmitter
2. Norepinephrine (NE) - the adrenergic transmitter

---

SECTION 1: THE SYMPATHETIC NERVOUS SYSTEM

1.1 The Story: "Fight or Flight" 🦁

• Run fast → increase heart rate, blood pressure
• Get oxygen → dilate airways
• Redirect blood to muscles → constrict gut/skin vessels
• See better → dilate pupils
• Mobilize energy → raise blood sugar
• Stop non-essential functions → slow digestion, stop urination

1.2 Anatomy of the Sympathetic System

SPINAL CORD (T1-L2 = "thoracolumbar")
        ↓ (Preganglionic fiber - SHORT)
  ACh released at GANGLION (near spine)
        ↓ (Postganglionic fiber - LONG)
  NOREPINEPHRINE (NE) released at organ
        ↓
  Binds ADRENERGIC RECEPTORS on organ
        ↓
  Sympathetic effect

1.3 The Adrenergic Receptors - The Entire Map

α1 Receptors (postsynaptic)

α2 Receptors (mainly presynaptic/feedback)

Key concept: α2 on the nerve terminal is an autoreceptor - when NE builds up, it feeds back to α2 to say "stop releasing more." Drugs like clonidine exploit this to lower BP centrally.

β1 Receptors

β2 Receptors

β3 Receptors

---

1.4 Key Sympathomimetic Drugs (Adrenergic Agonists)

Direct-Acting (act directly on receptor)

Indirect-Acting (increase NE at synapse)

---

1.5 Sympatholytic Drugs (Adrenergic Antagonists/Blockers)

α-Blockers

Side effect of α1 blockers: Postural hypotension (vessels can't constrict when standing) and reflex tachycardia (no vasoconstriction → heart compensates) α2 blockade by phentolamine causes NE release (removes the brake) → tachycardia

β-Blockers

β-Blocker effects: ↓ HR, ↓ BP, ↓ contractility, ↓ renin, bronchoconstriction (β2 block), mask hypoglycemia symptoms (block β2-mediated tremor and tachycardia of hypoglycemia)

---

SECTION 2: THE PARASYMPATHETIC NERVOUS SYSTEM

2.1 The Story: "Rest and Digest" 🌿

• Slow heart down → bradycardia
• Digest food → increase GI motility and secretions
• Focus vision (near) → constrict pupils, contract ciliary muscle
• Empty bladder → contract detrusor
• Reduce blood pressure → vasodilation

2.2 Anatomy of the Parasympathetic System

BRAINSTEM (CN III, VII, IX, X) and SACRAL CORD (S2-S4) = "Craniosacral"
        ↓ (Preganglionic fiber - LONG)
  ACh released at GANGLION (near or ON the organ)
        ↓ (Postganglionic fiber - SHORT)
  ACh released at organ
        ↓
  Binds MUSCARINIC RECEPTORS on organ
        ↓
  Parasympathetic effect

Key difference from sympathetic: Both pre- AND postganglionic parasympathetic fibers use ACh. Sympathetic uses ACh preganglionic but NE postganglionic.

---

SECTION 3: ACETYLCHOLINE (ACh) - THE CHOLINERGIC MESSENGER

3.1 Where ACh is Used (Complete Map)

ACh is released at:
1. ALL preganglionic fibers (both SNS and PNS) → ganglionic nicotinic receptors
2. ALL postganglionic PARASYMPATHETIC fibers → muscarinic receptors on organs
3. Postganglionic SYMPATHETIC to sweat glands → muscarinic receptors
4. Somatic motor neurons → NMJ nicotinic receptors on skeletal muscle
5. CNS neurons → both muscarinic and nicotinic
6. Adrenal medulla (preganglionic SNS) → ganglionic nicotinic receptors

3.2 How ACh is Made, Released, and Destroyed (6 Steps)

Step 1 - SYNTHESIS:
  Choline (from diet/recycling) + Acetyl-CoA
           ↓ (Choline acetyltransferase enzyme = ChAT)
           ACh formed in cytoplasm

Step 2 - STORAGE:
  ACh packaged into vesicles by active transport
  Each vesicle: ~10,000 ACh molecules + ATP (cotransmitter)
  [Botulinum toxin blocks this step - prevents vesicle docking]

Step 3 - RELEASE:
  Action potential arrives → voltage-gated Ca²⁺ channels open
  Ca²⁺ enters → vesicles fuse with membrane → exocytosis
  ACh floods into synaptic cleft

Step 4 - BINDING:
  ACh binds muscarinic OR nicotinic receptors
  → Physiologic effect occurs

Step 5 - DEGRADATION:
  AChE (Acetylcholinesterase) immediately cleaves ACh:
  ACh → Acetate + Choline
  (This happens in milliseconds - signal terminates rapidly)
  [OPs, carbamates, neostigmine block this step]

Step 6 - RECYCLING:
  Choline is transported back into presynaptic terminal
  (Choline transporter - rate-limiting step)
  → New ACh synthesized → cycle repeats

---

SECTION 4: AChE (ACETYLCHOLINESTERASE) - THE TERMINATOR

4.1 What AChE Does

• Synaptic cleft of all cholinergic synapses
• NMJ (neuromuscular junction)
• RBC membrane surface
• Brain tissue

• Plasma, liver, pancreas, heart
• Hydrolyzes succinylcholine and mivacurium in anesthesia

4.2 How AChE Works (The Chemistry)

Normal hydrolysis:
ACh enters active site of AChE
         ↓
Esteratic site (serine-OH) attacks ACh
         ↓
Tetrahedral intermediate formed
         ↓
Acetylated enzyme + choline released
         ↓
Water attacks → enzyme regenerated + acetate released
         ↓
AChE ready for next ACh molecule
(Complete in < 1 millisecond!)

4.3 Drugs That Inhibit AChE (Cholinesterase Inhibitors)

Reversible AChE Inhibitors (Therapeutic Use)

Irreversible AChE Inhibitors (Poisons/Weapons)

---

SECTION 5: MUSCARINIC RECEPTORS (M1-M5)

5.1 The "Muscarine Test"

5.2 Complete Muscarinic Receptor Map

M1 - "Mind" Receptor (CNS + Stomach)

• Pirenzepine (M1 blocker): selective peptic ulcer treatment (minimal side effects)
• Donepezil, rivastigmine (indirectly ↑ ACh at M1): Alzheimer's

M2 - "Muscle (Heart)" Receptor

• Atropine (M2 blocker): reverses bradycardia, increases HR
• Digoxin toxicity often produces M2 overstimulation → atropine used to treat

M3 - "Main Effects" Receptor (The Busiest)

• Ipratropium/tiotropium (M3 blockers in airways): COPD/asthma bronchodilators
• Oxybutynin, tolterodine, solifenacin (M3 bladder blockers): overactive bladder
• Pilocarpine (M3 agonist, eye drops): glaucoma - opens trabecular meshwork
• Atropine (blocks M3): causes all OPPOSITE effects

M4 - Inhibitory CNS Receptor

M5 - Vascular in CNS

---

5.3 The "SLUDGE" Mnemonic - M3 Receptor Overstimulation

S - Salivation
L - Lacrimation
U - Urination
D - Defecation
G - GI cramping
E - Emesis

• Bradycardia (M2)
• Bronchospasm (M3)
• Bronchorrhea (M3)

---

5.4 Muscarinic Agonist Drugs

5.5 Muscarinic Antagonist Drugs (Anticholinergics / Antimuscarinics)

---

SECTION 6: NICOTINIC RECEPTORS (NM and NN)

6.1 The "Nicotine Test"

6.2 Two Types of Nicotinic Receptors

NN (Neuronal Nicotinic) - "Neural"

Key point: NN receptors are in BOTH sympathetic and parasympathetic ganglia. Drugs blocking NN block ALL autonomic function simultaneously.

• Nicotine (ganglionic stimulant): activates both SNS + PNS ganglia, net effect depends on which predominates in each organ
• Hexamethonium (ganglionic blocker): historical antihypertensive; blocked all autonomic ganglia → dramatic fall in BP; not used clinically now
• Mecamylamine: ganglionic blocker; used for severe hypertension (rare), nicotine addiction research

NM (Muscle Nicotinic) - "Motor"

Depolarizing (Phase 1 → Phase 2):

Non-depolarizing (Competitive antagonists - block without activating):

---

SECTION 7: THE COMPLETE RECEPTOR-DRUG MAP

7.1 One Table to Rule Them All

---

SECTION 8: ORGAN-BY-ORGAN EFFECTS - SYMPATHETIC vs. PARASYMPATHETIC

8.1 The Organ Effects Table

• SNS = "E's" → Epi, Exercise, Emergency: ↑ everything except GI/bladder/salivation
• PNS = "D's" → Digestion, Defecation, Diuresis, Dilation (pupils relax after work) - does all housekeeping

---

SECTION 9: THE DRUG DRUG MAP - COMMON CLINICAL SCENARIOS

9.1 Cholinergic Crisis (OP poisoning, AChE inhibitor excess)

↑ ACh at muscarinic → SLUDGE + Bradycardia + Bronchospasm
↑ ACh at NMJ (nicotinic) → Fasciculations → Paralysis
↑ ACh in CNS → Seizures, coma

• Atropine → blocks muscarinic excess (M1, M2, M3) → dries secretions, reverses bradycardia, opens bronchi
• Pralidoxime → reactivates AChE (before aging) → restores NE function
• Benzodiazepines → control seizures

9.2 Anticholinergic Crisis (Atropine OD, Jimsonweed, TCAs)

No M2 stimulation → Tachycardia
No M3 stimulation → Dry skin, mydriasis, bronchodilation, urinary retention, ileus
No M1/M4 in CNS → "Mad as a hatter" - delirium, hallucinations
No sweating (M3) → Hyperthermia

• Physostigmine → crosses BBB, inhibits AChE → ↑ ACh everywhere → reverses all effects

9.3 Anaphylaxis

Histamine → α1-like on vessels → vasodilation → ↓ BP
Histamine → M3-like on bronchi → bronchoconstriction

• Epinephrine (Epi/adrenaline) is perfect: α1 → vasoconstriction ↑ BP; β1 → ↑ HR; β2 → bronchodilation

9.4 Hypertension

• β1 blockade (metoprolol) → ↓ HR, ↓ renin
• α1 blockade (prazosin) → vasodilation
• α2 stimulation (clonidine) → ↓ central sympathetic outflow

9.5 Glaucoma (Increased intraocular pressure)

• Pilocarpine (M3 agonist) → contracts ciliary muscle, opens trabecular meshwork → ↑ aqueous drainage → ↓ IOP
• Timolol (β2 blocker) → reduces aqueous humor production

---

SECTION 10: THE COMPLETE SUMMARY DIAGRAM

AUTONOMIC NERVOUS SYSTEM
          │
    ┌─────┴─────┐
SYMPATHETIC   PARASYMPATHETIC
(Thoracolumbar) (Craniosacral)
T1-L2         CN III,VII,IX,X + S2-S4
    │                │
Preganglionic:  Preganglionic:
   ACh→NN          ACh→NN
    │                │
GANGLION         GANGLION
    │                │
Postganglionic: Postganglionic:
   NE→α,β          ACh→M
    │                │
   ORGAN           ORGAN
"Fight or flight"  "Rest and digest"
    │
Adrenal Medulla → Epi(80%) + NE(20%) → Blood

SOMATIC SYSTEM
Motor neuron → ACh→NM → Skeletal muscle contraction

NEUROTRANSMITTER SUMMARY:
ACh → Nicotinic (all ganglia + NMJ) + Muscarinic (PNS organs + sweat glands)
NE  → Adrenergic (SNS organs)
Epi → Same as NE but with stronger β2

---

Quick Memory Tricks

---

• Lippincott Illustrated Reviews: Pharmacology, Chapters 3-5 (ANS, Cholinergic, Adrenergic)
• Morgan & Mikhail's Clinical Anesthesiology, 7th Ed, Cholinergic Pharmacology
• Katzung's Basic and Clinical Pharmacology, 16th Ed
• Goodman & Gilman's The Pharmacological Basis of Therapeutics
• Barash's Clinical Anesthesia, 9th Ed